Efruxifermin (EFX): Audience

Efruxifermin (EFX) is a novel therapy developed by Akero Therapeutics aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). It is positioned as a potentially best-in-class treatment for this serious metabolic disease.